Detalhe da pesquisa
1.
Efficacy and safety of ligelizumab in adults and adolescents with chronic spontaneous urticaria: results of two phase 3 randomised controlled trials.
Lancet
; 403(10422): 147-159, 2024 Jan 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-38008109
2.
Secukinumab dosing every 2 weeks demonstrated superior efficacy compared with dosing every 4 weeks in patients with psoriasis weighing 90 kg or more: results of a randomized controlled trial.
Br J Dermatol
; 186(6): 942-954, 2022 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-34981829
3.
A phase 3 open-label, randomized multicenter study to evaluate efficacy and safety of secukinumab in pediatric patients with moderate to severe plaque psoriasis: 24-week results.
J Am Acad Dermatol
; 86(1): 122-130, 2022 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34555481
4.
Secukinumab demonstrates efficacy, safety, and tolerability upon administration by 2 ml autoinjector in adult patients with plaque psoriasis: 52-week results from MATURE, a randomized, placebo-controlled trial.
Dermatol Ther
; 35(3): e15285, 2022 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-34954841
5.
Comparison of pharmacokinetics, safety and tolerability of secukinumab administered subcutaneously using different delivery systems in healthy volunteers and in psoriasis patients.
Br J Clin Pharmacol
; 86(2): 338-351, 2020 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-31658377
6.
Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): a randomised, double-blind, placebo-controlled, phase 3 trial.
Lancet
; 386(9999): 1137-46, 2015 Sep 19.
Artigo
em Inglês
| MEDLINE | ID: mdl-26135703
7.
Comprehensive Assessment of Pharmacokinetics, Pharmacodynamics, and Tolerability of Ligelizumab in Healthy Volunteers and Patients with Chronic Spontaneous Urticaria to Optimize Its Subcutaneous Delivery System.
Pharmaceutics
; 15(9)2023 Sep 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-37765235
8.
Secukinumab in Pediatric Patients with Plaque Psoriasis: Pooled Safety Analysis from Two Phase 3 Randomized Clinical Trials.
Am J Clin Dermatol
; 24(5): 821-835, 2023 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-37341961
9.
Efficacy of Secukinumab Across Subgroups and Overall Safety in Pediatric Patients with Moderate to Severe Plaque Psoriasis: Week 52 Results from a Phase III Randomized Study.
Paediatr Drugs
; 24(4): 377-387, 2022 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-35698000
10.
Efficacy, tolerability, patient usability, and satisfaction with a 2 mL pre-filled syringe containing secukinumab 300 mg in patients with moderate to severe plaque psoriasis: results from the phase 3 randomized, double-blind, placebo-controlled ALLURE study.
J Dermatolog Treat
; 33(3): 1718-1726, 2022 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-33896356
11.
Association of Secukinumab Treatment With Tuberculosis Reactivation in Patients With Psoriasis, Psoriatic Arthritis, or Ankylosing Spondylitis.
JAMA Dermatol
; 157(1): 43-51, 2021 01 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-33001147
12.
Secukinumab demonstrates high efficacy and a favorable safety profile over 52 weeks in Chinese patients with moderate to severe plaque psoriasis.
Chin Med J (Engl)
; 133(22): 2665-2673, 2020 Nov 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-33060370
13.
Secukinumab is Superior to Ustekinumab in Clearing Skin in Patients with Moderate to Severe Plaque Psoriasis (16-Week CLARITY Results).
Dermatol Ther (Heidelb)
; 8(4): 571-579, 2018 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-30334147
14.
Efficacy and safety of secukinumab over 52 weeks in Chinese psoriasis patients with concomitant psoriatic arthritis.
Chin Med J (Engl)
; 134(21): 2629-2631, 2021 Sep 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-34748527